Stress Urinary Incontinence – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Stress Urinary Incontinence – Drugs In Development, 2024 report and make more profitable business decisions.
Stress urinary incontinence (SUI) is the involuntary, sudden loss of urine secondary to increased intraabdominal pressure that is affecting the patient’s quality of life. Physical activities precipitating SUI include laughing, sneezing, straining, coughing, or exercising. Patients may refer to a sudden loss of urine as “leaking”, “dripping”, or “flooding”. The patient may initially present with urinary complaints of frequency, urgency, and dysuria.
The Stress Urinary Incontinence drugs in development market research report provide comprehensive information on the therapeutics under development for Stress Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stress Urinary Incontinence and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Stress Urinary Incontinence | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 10 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Stress Urinary Incontinence therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Stress Urinary Incontinence pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Stress Urinary Incontinence treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncChangchun Jinsai Pharmaceutical Co Ltd
Cook MyoSite Inc
Innovacell Biotechnologie AG
Medipreneur Co Ltd
MUVON Therapeutics AG
Rion Inc
Stanford University
Taiho Pharmaceutical Co Ltd
Versameb AG
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Stress Urinary Incontinence reports